JPRN-UMIN000041304
Completed
未知
Observational Study on treatment status and adherence in patients with Bipolar disorder Using claims database in Japan. - Observational Study on treatment status and adherence in patients with Bipolar disorder Using claims database in Japan.
ConditionsBipolar disorder
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Bipolar disorder
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Enrollment
- 13788
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who meet the following 1\)Patients who started treatment for Schizophrenia, dementia, autism and ADHD during the enrollment period. 2\)Patients who started treatment for bipolar disorder or started treatment with target drug for bipolar disorder for 365 days from the Index date.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
identifying the reasons for not adhering to treatment in stroke patients and to find the burden of their care giverCTRI/2018/06/014502nil
Active, not recruiting
Not Applicable
Prospective observational study for Treatment resistance related gene screening using plasma circulating tumor DNA in the third generation EGFR-TKI Osimertinib therapyJPRN-jRCTs031180051Tamiya Akihiro180
Active, not recruiting
Not Applicable
Observational study to assess compliance, safety issues and treatment response to single pill once daily regimen of Tenofovir, Lamivudine, Efavirenz (TLE) in HIV infected adult patientsHealth Condition 1: null- HIV patients receiving ARTCTRI/2016/03/006742Department of Pharmacology IPGMER150
Completed
Not Applicable
Observational study for treatment outcome in patients with HER2-positive metastatic breast cancer who received pertuzumab combination chemotherapy.Breast cancerJPRN-UMIN000012210Kurume University Hospital10
Not yet recruiting
Not Applicable
Observational study to assess treatment patterns and clinical outcome in advance and/or recurrent endometrial cancer after adjuvant chemotherapyEndometrial cancerJPRN-UMIN000050897JGOG400